Prosecution Insights
Last updated: April 19, 2026

A2 Biotherapeutics, Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
1
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18253721 ADOPTIVE CELL THERAPY FOR TREATMENT OF CANCER ASSOCIATED WITH LOSS OF HETEROZYGOSITY HECK, BRYAN WILLIAM 1643 Non-Final OA May 19, 2023
18020837 COMPOSITIONS AND METHODS FOR TREATING CANCERS BUTTICE, AUDREY L 1647 Non-Final OA Feb 10, 2023
18165623 COMPOSITIONS AND METHODS FOR TREATING EGFR POSITIVE CANCERS CANELLA, KAREN A 1643 Non-Final OA Feb 07, 2023
18062873 COMPOSITIONS AND METHODS FOR TREATING MESOTHELIN POSITIVE CANCERS SPENCE, JENNIFER SUZANNE 1633 Non-Final OA Dec 07, 2022
17757056 NUCLEIC ACID ENCODING LILRB1-BASED CHIMERIC ANTIGEN RECEPTOR O'BRIEN, LEA S 1646 Non-Final OA Jun 08, 2022
17480501 CONTROLLING PROXIMITY OF IMMUNE CELL RECEPTORS TIWARI, VYOMA SHUBHAM 1634 Final Rejection Sep 21, 2021

Managing A2 Biotherapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month